Find Clinical Trial

A study to find out how healthy people tolerate a new drug called S221237.


← Back
Study Phase

Phase 1

Therapeutic Area

Nervous system diseases

IndicationParkinson's disease
SponsorInstitut De Recherches Internationales Servier (IRIS)
Active substance/
Medical device

S221237

Active Substance CodeS221237
Protocol CodeCL1-221237-002
Eu CT2024-519381-53-00


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility